{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,2,10]],"date-time":"2024-02-10T00:12:44Z","timestamp":1707523964860},"reference-count":13,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2023,8,25]]},"DOI":"10.7759\/cureus.44085","type":"journal-article","created":{"date-parts":[[2023,8,25]],"date-time":"2023-08-25T07:57:50Z","timestamp":1692950270000},"source":"Crossref","is-referenced-by-count":0,"title":["Pregabalin Dependence and Management in a 55-Year-Old Female with Chronic Low Back Pain"],"prefix":"10.7759","author":[{"given":"Abhimanyu","family":"Vasudeva","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Richa","family":"Tripathi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.4103\/0972-6748.328855","article-title":"A case of pregabalin addiction","volume":"30","author":"Sahu S","year":"2021","unstructured":"Sahu S, Kumar S, Chaudhury S, Saldanha D. A case of pregabalin addiction. Ind Psychiatry J. 2021, 30:S352-3. 10.4103\/0972-6748.328855","journal-title":"Ind Psychiatry J"},{"key":"ref2","article-title":"Pregabalin","author":"Cross AL","year":"2022","unstructured":"Cross AL, Viswanath O, Sherman Al. Pregabalin. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2022."},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1111\/j.1755-5949.2009.00120.x","article-title":"Pregabalin in the treatment of alcohol and benzodiazepines dependence","volume":"16","author":"Oulis P","year":"2010","unstructured":"Oulis P, Konstantakopoulos G. Pregabalin in the treatment of alcohol and benzodiazepines dependence. CNS Neurosci Ther. 2010, 16:45-50. 10.1111\/j.1755-5949.2009.00120.x","journal-title":"CNS Neurosci Ther"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.3389\/fpsyt.2019.00228","article-title":"Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review","volume":"10","author":"Ahmed S","year":"2019","unstructured":"Ahmed S, Bachu R, Kotapati P, et al.. Use of gabapentin in the treatment of substance use and psychiatric disorders: a systematic review. Front Psychiatry. 2019, 10:228. 10.3389\/fpsyt.2019.00228","journal-title":"Front Psychiatry"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1016\/j.euroneuro.2017.08.430","article-title":"How addictive are gabapentin and pregabalin? A systematic review","volume":"27","author":"Bonnet U","year":"2017","unstructured":"Bonnet U, Scherbaum N. How addictive are gabapentin and pregabalin? A systematic review. Eur Neuropsychopharmacol. 2017, 27:1185-215. 10.1016\/j.euroneuro.2017.08.430","journal-title":"Eur Neuropsychopharmacol"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1016\/j.psychres.2021.114193","article-title":"Gabapentinoids: the rise of a new misuse epidemics?","volume":"305","author":"Hofmann M","year":"2021","unstructured":"Hofmann M, Besson M. Gabapentinoids: the rise of a new misuse epidemics?. Psychiatry Res. 2021, 305:114193. 10.1016\/j.psychres.2021.114193","journal-title":"Psychiatry Res"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1177\/02537176221122389","article-title":"Pregabalin use\/misuse: a source of consternation in Western Punjab","volume":"45","author":"Aneja J","year":"2023","unstructured":"Aneja J, Singh J. Pregabalin use\/misuse: a source of consternation in Western Punjab. Indian J Psychol Med. 2023, 45:206-7. 10.1177\/02537176221122389","journal-title":"Indian J Psychol Med"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1007\/s40122-020-00189-x","article-title":"Gabapentinoid benefit and risk stratification: mechanisms over myth","volume":"9","author":"McAnally H","year":"2020","unstructured":"McAnally H, Bonnet U, Kaye AD. Gabapentinoid benefit and risk stratification: mechanisms over myth. Pain Ther. 2020, 9:441-52. 10.1007\/s40122-020-00189-x","journal-title":"Pain Ther"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-020-01432-7","article-title":"Abuse and misuse of pregabalin and gabapentin: a systematic review update","volume":"81","author":"Evoy KE","year":"2021","unstructured":"Evoy KE, Sadrameli S, Contreras J, Covvey JR, Peckham AM, Morrison MD. Abuse and misuse of pregabalin and gabapentin: a systematic review update. Drugs. 2021, 81:125-56. 10.1007\/s40265-020-01432-7","journal-title":"Drugs"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1007\/s40265-021-01494-1","article-title":"Comment on \"Abuse and misuse of pregabalin and gabapentin: a systematic review update\"","volume":"81","author":"Bonnet U","year":"2021","unstructured":"Bonnet U, McAnally H, Scherbaum N. Comment on \"Abuse and misuse of pregabalin and gabapentin: a systematic review update\". Drugs. 2021, 81:611-4. 10.1007\/s40265-021-01494-1","journal-title":"Drugs"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1016\/j.lanepe.2022.100579","article-title":"Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study","volume":"27","author":"Ashworth J","year":"2023","unstructured":"Ashworth J, Bajpai R, Muller S, et al.. Trends in gabapentinoid prescribing in UK primary care using the Clinical Practice Research Datalink: an observational study. Lancet Reg Health Eur. 2023, 27:100579. 10.1016\/j.lanepe.2022.100579","journal-title":"Lancet Reg Health Eur"},{"key":"ref12","article-title":"Prescription of controlled substances: benefits and risks","author":"Preuss CV","year":"2023","unstructured":"Preuss CV, Kalava A, King KC. Prescription of controlled substances: benefits and risks. StatPearls [Internet]. StatPearls Publishing, Treasure Island (FL); 2023."},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.2147\/RMHP.S168504","article-title":"Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance","volume":"11","author":"Peckham AM","year":"2018","unstructured":"Peckham AM, Ananickal MJ, Sclar DA. Gabapentin use, abuse, and the US opioid epidemic: the case for reclassification as a controlled substance and the need for pharmacovigilance. Risk Manag Healthc Policy. 2018, 11:109-16. 10.2147\/RMHP.S168504","journal-title":"Risk Manag Healthc Policy"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/179977-pregabalin-dependence-and-management-in-a-55-year-old-female-with-chronic-low-back-pain","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,2,9]],"date-time":"2024-02-09T19:55:33Z","timestamp":1707508533000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/179977-pregabalin-dependence-and-management-in-a-55-year-old-female-with-chronic-low-back-pain"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,25]]},"references-count":13,"URL":"https:\/\/doi.org\/10.7759\/cureus.44085","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2023,8,25]]}}}